{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:41:10Z","timestamp":1791895270612,"version":"4.3.4"},"reference-count":36,"publisher":"American Diabetes Association","issue":"Supplement_2","content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2008,2,1]]},"abstract":"<jats:p>Diabetes is characterized by glycemic disorders that include both sustained chronic hyperglycemia and acute glucose fluctuations. There is now cogent evidence for the deleterious effects of sustained chronic hyperglycemia that results in excessive protein glycation and generation of oxidative stress. The role of glucose variability from peaks to nadirs is less documented, but there are many reasons to think that both upward (postprandial) and downward (interprandial) acute fluctuations of glucose around a mean value activate the oxidative stress. As a consequence, it is strongly suggested that a global antidiabetic strategy should be aimed at reducing to a minimum the different components of dysglycemia (i.e., A1C, fasting and postprandial glucose, as well as glucose variability). All the therapeutic agents that act on postprandial glucose excursions seem of particular interest for reducing the latter parameter (i.e., the glucose instability). Particular attention should be paid to such emerging therapeutic agents as the glucagon-like peptide 1 agonists and the dipeptidyl peptidase (DPP)-IV inhibitors that act through the incretin pathway.<\/jats:p>","DOI":"10.2337\/dc08-s241","type":"journal-article","created":{"date-parts":[[2008,1,28]],"date-time":"2008-01-28T17:26:40Z","timestamp":1201541200000},"page":"S150-S154","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":231,"title":["Glycemic Variability"],"prefix":"10.2337","volume":"31","author":[{"given":"Louis","family":"Monnier","sequence":"first","affiliation":[{"name":"Department of Metabolic Diseases, Lapeyronie Hospital, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claude","family":"Colette","sequence":"additional","affiliation":[{"name":"Laboratory of Human Nutrition, University Institute of Clinical Research, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","reference":[{"key":"2022031216361146000_R1","doi-asserted-by":"crossref","unstructured":"Kannel WB, Mc Gee DL: Diabetes and cardiovascular diseases: the Framingham Study. JAMA\u2008241: 2035\u20132038, 1979","DOI":"10.1001\/jama.241.19.2035"},{"key":"2022031216361146000_R2","unstructured":"Laakso L, Lehto S: Epidemiology of macrovascular disease in diabetes. Diabetes Rev\u20085:294\u2013315, 1997"},{"key":"2022031216361146000_R3","doi-asserted-by":"crossref","unstructured":"Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med\u2008329:977\u2013986, 1993","DOI":"10.1056\/NEJM199309303291401"},{"key":"2022031216361146000_R4","doi-asserted-by":"crossref","unstructured":"Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ\u2008321:405\u2013412, 2000","DOI":"10.1136\/bmj.321.7258.405"},{"key":"2022031216361146000_R5","doi-asserted-by":"crossref","unstructured":"Eastman RC, Javitt JC, Herman WH, Dasbach EJ, Zbrozek AS, Dong F, Manninen D, Gardfield SA, Copley-Merriman C, Maier W, Eastman JF, Kotsanos J, Cowie CC, Harris M: Model of complications of NIDDM 1: Model constructions and assumptions. Diabetes Care\u200820:725\u2013734, 1997","DOI":"10.2337\/diacare.20.5.725"},{"key":"2022031216361146000_R6","doi-asserted-by":"crossref","unstructured":"Gaede P, Vedel P, Larsen N, Jensen GVH, Parving HH, Pedersen O: Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med\u2008348:383\u2013393, 2003","DOI":"10.1056\/NEJMoa021778"},{"key":"2022031216361146000_R7","doi-asserted-by":"crossref","unstructured":"DCCT Research Group: The relationship of a glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial. Diabetes\u200844:968\u2013983, 1995","DOI":"10.2337\/diab.44.8.968"},{"key":"2022031216361146000_R8","doi-asserted-by":"crossref","unstructured":"Klein R: Hyperglycemia and microvascular disease in diabetes. Diabetes Care\u200818:258\u2013268, 1995","DOI":"10.2337\/diacare.18.2.258"},{"key":"2022031216361146000_R9","doi-asserted-by":"crossref","unstructured":"Brownlee M: Biochemistry and molecular cell biology of diabetic complications. Nature\u2008414:813\u2013820, 2001","DOI":"10.1038\/414813a"},{"key":"2022031216361146000_R10","doi-asserted-by":"crossref","unstructured":"Brownlee M: Banting lecture 2004. The pathobiology of diabetic complications: a unifying mechanism. Diabetes\u200854:1615\u20131625, 2005","DOI":"10.2337\/diabetes.54.6.1615"},{"key":"2022031216361146000_R11","doi-asserted-by":"crossref","unstructured":"Avignon A, Radauceanu A, Monnier L: Nonfasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes. Diabetes Care\u200820:1822\u20131826, 1997","DOI":"10.2337\/diacare.20.12.1822"},{"key":"2022031216361146000_R12","doi-asserted-by":"crossref","unstructured":"Bonora E, Calcaterra F, Lombardi S, Bonfante N, Formentini G, Bonadonna RC, Muggeo M: Plasma glucose levels throughout the day and HbA1c interrelationships in type 2 diabetes: implications for treatment and monitoring of metabolic control. Diabetes Care\u200824:2023\u20132029, 2001","DOI":"10.2337\/diacare.24.12.2023"},{"key":"2022031216361146000_R13","doi-asserted-by":"crossref","unstructured":"El-Kebbi IM, Ziemer DC, Cook CB, Gallina DL, Barnes CS, Philipps LS: Utility of casual postprandial glucose levels in type 2 diabetes management. Diabetes Care\u200827:335\u2013339, 2004","DOI":"10.2337\/diacare.27.2.335"},{"key":"2022031216361146000_R14","doi-asserted-by":"crossref","unstructured":"Rohlfing CL, Wiedmeyer HS, Little RR, England JD, Tennill A, Godstein DE: Defining the relationship between plasma glucose and HbA1c. Diabetes Care\u200825:275\u2013278, 2002","DOI":"10.2337\/diacare.25.2.275"},{"key":"2022031216361146000_R15","doi-asserted-by":"crossref","unstructured":"American Diabetes Association: Standards of medical care in diabetes. Diabetes Care\u200829 (Suppl. 1):S4\u2013S42, 2006","DOI":"10.2337\/diacare.29.s1.06.s4"},{"key":"2022031216361146000_R16","doi-asserted-by":"crossref","unstructured":"Sacks DB, Bruns DE, Goldstein DE, Mac Laren NK, Mc Donald JM, Parrott M: Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus (Position Statement). Diabetes Care\u200825:750\u2013786, 2002","DOI":"10.2337\/diacare.25.4.750"},{"key":"2022031216361146000_R17","doi-asserted-by":"crossref","unstructured":"Gorus F, Mathieu C, Gerlo E: How should HbA1c measurements be reported? Diabetologia\u200849:7\u201310, 2006","DOI":"10.1007\/s00125-005-0073-7"},{"key":"2022031216361146000_R18","doi-asserted-by":"crossref","unstructured":"U.K. Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet\u2008352:837\u2013853, 1998","DOI":"10.1016\/S0140-6736(98)07019-6"},{"key":"2022031216361146000_R19","doi-asserted-by":"crossref","unstructured":"Hanefeld M, Fischer S, Julius U, Schulze J, Schwanebeck U, Schmechel H, Ziegelasch HJ, Lindner J: Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Interventional Study, 11-year follow-up. Diabetologia\u200839:1577\u20131583, 1996","DOI":"10.1007\/s001250050617"},{"key":"2022031216361146000_R20","doi-asserted-by":"crossref","unstructured":"Ceriello A, Hanefeld M, Leiter L, Monnier L, Moses A, Owens D, Tajima N, Tuomilehto J: Postprandial glucose regulation and diabetic complications. Arch Intern Med\u2008164:2090\u20132095, 2004","DOI":"10.1001\/archinte.164.19.2090"},{"key":"2022031216361146000_R21","doi-asserted-by":"crossref","unstructured":"Cavalot F, Petrelli A, Traversa M, Bonomo K, Fiora E, Conti M, Anfossi G, Costa G, Trovati M: Postprandial blood glucose is a stronger predictor of cardiovascular events than fasting blood glucose in type 2 diabetes mellitus, particularly in women: lessons from the San Luigi Gonzaga Diabetes Study. J Clin Endocrinol Metab\u200891:813\u2013819, 2006","DOI":"10.1210\/jc.2005-1005"},{"key":"2022031216361146000_R22","doi-asserted-by":"crossref","unstructured":"Ceriello A: Postprandial hyperglycemia and diabetes complications: is it time to treat? Diabetes\u200854:1\u20137, 2005","DOI":"10.2337\/diabetes.54.1.1"},{"key":"2022031216361146000_R23","doi-asserted-by":"crossref","unstructured":"Morrow JD, Hill KE, Burk RF, Nammour TM, Badr KF, Roberts LJ: A series of prostaglandin F2-like compounds are produced in vivo in humans by non-cyclooxygenase free radical-catalyzed mechanism. Proc Natl Acad Sci U S A\u200887:9383\u20139387, 1991","DOI":"10.1073\/pnas.87.23.9383"},{"key":"2022031216361146000_R24","doi-asserted-by":"crossref","unstructured":"Roberts LJ, Morrow JD: Measurement of F(2)-isoprostanes as an index of oxidative stress in vivo. Free Radic Bio Med\u200828:505\u2013513, 2000","DOI":"10.1016\/S0891-5849(99)00264-6"},{"key":"2022031216361146000_R25","doi-asserted-by":"crossref","unstructured":"Basu S: Metabolism of 8-iso-prostaglandin F2\u03b1. FEBS Lett\u2008428:32\u201336, 1998","DOI":"10.1016\/S0014-5793(98)00481-5"},{"key":"2022031216361146000_R26","doi-asserted-by":"crossref","unstructured":"Davi G, Falco A, Patrono C: Lipid peroxidation in diabetes mellitus. Antioxid Redox Signal\u20087:256\u2013258, 2005","DOI":"10.1089\/ars.2005.7.256"},{"key":"2022031216361146000_R27","doi-asserted-by":"crossref","unstructured":"Natarajan R, Lanting L, Gonzales N, Nadler J: Formation of an F2-isoprostane in vascular smooth muscle cells by elevated glucose and growth factors. Am J Physiol\u2008271:159\u2013165, 1996","DOI":"10.1152\/ajpheart.1996.271.1.H159"},{"key":"2022031216361146000_R28","doi-asserted-by":"crossref","unstructured":"Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol JP, Colette C: Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA\u2008295:1681\u20131687, 2006","DOI":"10.1001\/jama.295.14.1681"},{"key":"2022031216361146000_R29","doi-asserted-by":"crossref","unstructured":"Ceriello A, Quagliaro L, Catone B, Pascon R, Piazzola M, Bais B, Marra G, Tonutti L, Taboga C, Motz E: Role of hyperglycemia in nitrotyrosine postprandial generation. Diabetes Care\u200825:1439\u20131443, 2002","DOI":"10.2337\/diacare.25.8.1439"},{"key":"2022031216361146000_R30","doi-asserted-by":"crossref","unstructured":"Sampson MJ, Gopaul N, Davies IR, Hughes DA, Carrier MJ: Plasma F2 isoprostanes: direct evidence of increased free radical damage during acute hyperglycemia in type 2 diabetes. Diabetes Care\u200825:537\u2013541, 2002","DOI":"10.2337\/diacare.25.3.537"},{"key":"2022031216361146000_R31","doi-asserted-by":"crossref","unstructured":"Service FJ, Molnar GD, Rosevear JW, Ackerman E, Gatewood LC, Taylor WF: Mean amplitude of glycemic excursions, a measure of diabetic instability. Diabetes\u200819:644\u2013655, 1970","DOI":"10.2337\/diab.19.9.644"},{"key":"2022031216361146000_R32","doi-asserted-by":"crossref","unstructured":"Kilpatrick ES, Rigby AS, Atkin SL: The effect of glucose variability on the risk of microvascular complications in type 1 diabetes. Diabetes Care\u200829:1486\u20131490, 2006","DOI":"10.2337\/dc06-0293"},{"key":"2022031216361146000_R33","unstructured":"Buckingham B, Black J, Wilson DM: Continuous glucose monitoring. Current Opin Endocrinol Diabetes\u200812:273\u2013279, 2005"},{"key":"2022031216361146000_R34","doi-asserted-by":"crossref","unstructured":"Riddle MC, Rosenstock J, Gerich J, on behalf of the Insulin Glargin 4002 Study Investigators: The Treat-to-Target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care\u200826:3080\u20133086, 2003","DOI":"10.2337\/diacare.26.11.3080"},{"key":"2022031216361146000_R35","doi-asserted-by":"crossref","unstructured":"Yki-Ja\u0308rvinen H, Kauppinen-Ma\u0308kelin R, Tiikkainen M, Va\u0308ha\u0308talo M, Virtamo H, Nikkila\u0308 K, Tulokas T, Hulme S, Hardy K, McNulty S, Ha\u0308nninen J, Leva\u0308nen H, Lahdenpera\u0308 S, Lehtonen R, Ryysy L: Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia\u200849:442\u2013451, 2006","DOI":"10.1007\/s00125-005-0132-0"},{"key":"2022031216361146000_R36","doi-asserted-by":"crossref","unstructured":"Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG, for the GWAA Study Group: Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes. Ann Intern Med\u2008143:559\u2013569, 2005","DOI":"10.7326\/0003-4819-143-8-200510180-00006"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/31\/Supplement_2\/S150\/469347\/zdc1020800s150.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/31\/Supplement_2\/S150\/469347\/zdc1020800s150.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T12:08:42Z","timestamp":1647086922000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/31\/Supplement_2\/S150\/24843\/Glycemic-VariabilityShould-we-and-can-we-prevent"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,2,1]]},"references-count":36,"journal-issue":{"issue":"Supplement_2","published-print":{"date-parts":[[2008,2,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc08-s241","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,2,1]]}}}